IMPORTANCE Given recent advances in screening mammography and adjuvant therapy (treatment), quantifying their separate and combined effects on US breast cancer mortality reductions by molecular subtype could guide future decisions to reduce disease burden.
B reast cancer mortality rates have been steadily declining over time in the United States. 1 Simulation models developed within the Cancer Intervention and Surveillance Network (CISNET) estimated that screening mammography and adjuvant therapy (treatment) contributed approximately equally to the reduction in breast cancer mortality from 1975 to 2000. 2 Since then, mammography has transitioned from plain-film to digital technology optimized for tumor detection. 3, 4 At the same time, there have been advances in molecularly targeted treatments based on expression of estrogen-receptor (ER) and human epidermal growth factor receptor 2 (ERBB2, formerly HER2 or HER2/neu), including aromatase inhibitors for ER+, and trastuzumab for ERBB2+ cancers. In addition, there have been advances in chemotherapy, particularly increasing use of taxanes. 5, 6 It is not known how screening and treatment advances have contributed to recent population-level, molecular subtype-specific breast cancer mortality rates. No single national registry contains sufficient information to assess this progress. Moreover, most clinical trials do not consider both screening and treatment effects and do not readily translate to population effect. Given these circumstances, simulation modeling can be useful to integrate high-quality data from randomized controlled trials, large observational studies, and population registries to estimate the relative contributions of advances on population-level mortality. 2 In this report, 6 CISNET models compared the separate and combined contribution associated with screening and treatment on US breast cancer mortality rates by molecular subtype from 2000 to 2012.
Methods
The institutional review board at Georgetown University, the site of the CISNET Breast Cancer Coordinating Center, approved the study as exempt based on the use of deidentified data. The 6 CISNET models were Dana-Farber Cancer Institute (model D), 7 Erasmus Medical Center (model E), the absence of screening or treatment and then incorporated information on screening use and molecular subtypespecific treatment patterns to reproduce observed US incidence and mortality trends. 1, 20, 21 Screen-detection during the preclinical, screen-detectable period could result in diagnosis of earlier-stage or smaller tumors than diagnosed via symptomatic detection. This could translate into lower breast cancer mortality. Molecular subtype-specific, agespecific, and stage-specific treatment could reduce the hazards of breast cancer death (models D, G-E, M, and S) or result in cure for some cases (models E and W-H).
Model Input Parameters
Each group used a common set of inputs 22 based on their specific model structure, prior research, 15 and assumptions to best reproduce US breast cancer incidence and mortality trends (eTable 1 in the Supplement). 5, 6, [10] [11] [12] [13] [14] [15] [16] [17] [22] [23] [24] [25] [26] [27] Five models used age-period-cohort (APC) analyses to estimate 1975-2012 breast cancer incidence rates in the absence of screening (baseline incidence rate) 17, 25 ; model M applied a Bayesian approach to extend [1975] [1976] [1977] [1978] [1979] Surveillance Epidemiology and End Results (SEER) rates forward in time with a 4% (SD, 0.2%) annual increase. Plain-film and digital mammography sensitivity data from the Breast Cancer Surveillance Consortium (BCSC) for 1994-2012 were used to estimate sensitivity for detection of invasive and ductal carcinoma in situ cancers by age group, first vs subsequent screening, and time since last mammogram. Screening dissemination was derived from national survey data for age at first screen and subsequent screening frequency by birth cohort. 23, 24 Plain-film mammography was assumed before 2000. Digital mammography was phased-in starting in 2001 based on data from the BCSC (unpublished data) and the US Food and Drug Administration Mammography Quality Standards Act and Program.
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Molecular subtype-specific treatment dissemination was based on SEER patterns-of-care special studies for 26,27 and the National Comprehensive Cancer Network data for 1997 onwards. 14, 19 
Analyses
Each model simulated mortality rates under 4 intervention scenarios: (1) no screening or treatment (the baseline mortality rate), (2) screening alone, (3) treatment alone, and (4) combined screening and treatment. Rates were ageadjusted using the 2000 US Standard Population, 29 and outcomes were reported for women aged 30 to 79 years. The absolute mortality reductions associated with screening alone, treatment alone, or the combination in a given calendar year were calculated as the difference between the age-adjusted mortality rates predicted with intervention (scenarios 2, 3, or 4) and the baseline mortality rate in that year (scenario 1). The percentage of mortality reduction (hereafter referred to as mortality reduction) in a given calendar year was calculated as this difference divided by the baseline mortality rate in that calendar year (scenario 1; eTable 2 in the Supplement).
ER/ERBB2-specific mortality rates were computed by dividing the number of women who died of breast cancer with that subtype by the total breast cancer population at risk. In this manner, rates of all subtypes sum to the overall ageadjusted breast cancer mortality rate.
To estimate the separate contributions associated with screening and treatment to mortality reductions, we considered the modeled effects of screening alone and of treatment alone as a fraction of the combined modeled effect in each calendar year.
The relative contribution associated with screening vs treatment to the combination associated with both was computed as the ratio of the screening alone modeled effect to the sum of the screening alone modeled effect and the treatment alone modeled effect; the relative contribution associated with treatment was calculated similarly. Alternative approaches for computing these relative contributions were considered, and the main conclusions were unchanged (eMethods and eTable 3intheSupplement).
When considering the mortality reductions associated with each treatment intervention (eg, chemotherapy, hormonal therapy, and trastuzumab) to their combination, the relative contribution associated with the various treatments was decomposed by first considering the chemotherapy contribution; then the hormonal therapy contribution for ER+ cases, given chemotherapy contributions; and lastly, the contribution associated with trastuzumab for ERBB2+ cases, given the other therapies.
To estimate relative contributions associated with the most recent advancements, we compared the mortality reduction from 2000 to 2012. We focused on this difference to remove the modeled effect of changes in the baseline rate during this period.
Uncertainty Analysis
All results were reported by model and summarized as the mean and range across models. The range provided a measure of uncertainty because each model has different assumptions and structures to represent unobservable factors such as baseline incidence rate and breast cancer natural history. Results consistent across models were considered robust.
Results
Rates of mammography increased over time ( Figure 1A) , and plain-film was rapidly replaced by digital mammography starting in 2001 ( Figure 1B ). Treatment use varied by molecular subtype, age, and stage, with high rates of dissemination of recent advances ( Figure 1C ). Incorporating these observed screening and treatment patterns, the models reproduced observed age-adjusted incidence (eFigure 1 in the Supplement) and breast cancer mortality trends from 1975 to 2012 (Figure 2A) . Predicted mortality trends for a representative model (model G-E) illustrate that the mortality reduction associated with treatment alone increased faster than that associated with screening alone over time ( Figure 2B ).
Overall Breast Cancer Mortality in 2012
With the observed changes in screening technology and treatment regimens, we estimated a 49% (model range, 39%-58%) decrease in overall breast cancer mortality in 2012 relative to the estimated baseline rate in 2012 of 63 deaths (model range, 54-73) per 100 000 women ( Table 1 , column 4; eTable 2 in the Supplement). The estimated screening contribution associated with this mortality reduction was 37% (model range, 26%-51%), whereas the contribution associated with treatment was 63% (model range, 49%-74%). The larger contribution associated with treatment vs screening in 2012 was predicted in 5 of 6 models (Table 1, columns 7-8) . Note, in 2000, screening was associated with 44% (model range, 35%-60%) of the mortality reduction and treatment was associated with 56% (model range, 40%-65%) (eTable 5 in the Supplement).
The estimated 63% (model range, 49%-74%) relative contribution associated with treatment in 2012 consisted of 31% (model range, 22%-37%) from chemotherapy, 27% (model range, 18%-36%) from hormone therapy, and 4% (model range, 1%-6%) from trastuzumab ( Table 2) .
Molecular Subtype-Specific Breast Cancer Mortality in 2012
The ER+/ERBB2− subtype was estimated to be associated with 64% (model range, 61%-70%) of the overall mortality reduction in 2012 because it was the most common subtype (eTable 7intheSupplement).
Within-subtype analyses demonstrated significant variations in breast cancer mortality reduction in 2012 (vs estimated subtype-specific baseline rates; Table 1 , column 4). The estimated mortality reduction was largest for the ER+/ERBB2+ subtype at 58% (model range, 46%-71%), f o l l o w e db yE R +/ERBB2− at 51% (model range, 42%-59%), and ER−/ERBB2+ at 45% (model range, 33%-55%). The lowest mortality reduction was estimated for the ER−/ERBB2− subtype at 37% (model range, 27%-46%).
The estimated relative contributions associated with screening vs treatment also varied by molecular subtype, ranging from 31% (model range, 23%-41%) with screening vs 69% (model range, 59%-77%) with treatment for the ER+/ERBB2+ subtype to 48% (model range, 38%-57%) with screening vs 52% (model range, 43%-62%) with treatment for ER−/ERBB2− ( Table 1, columns 7-8) . The estimated relative contributions associated with specific treatments varied by subtype ( Table 2 ). For example, for the ER+/ERBB2+ subtype, of the 69% (model range, 59%-77%) relative contribution associated with treatment, 26% (model range, 15%-32%) was associated with chemotherapy, 29% (model range, 23%-36%) with hormone therapy, and 14% (model range, 9%-18%) with trastuzumab ( Table 2 ). For the ER−/ERBB2− subtype, the 52% (model range, 43%-62%) relative contribution associated with treatment was associated with chemotherapy alone.
Contribution Associated With Screening and Treatment Advances From 2000 To 2012
The estimated overall breast cancer mortality reduction in 2000 was 37% (model range, 27%-42%) relative to the estimated baseline rate in 2000 of 64 deaths (model range, 56-73) per 100 000 women ( Table 3 , column 2; eTable 2 in the Supplement). The estimated overall breast cancer mortality reduction in 2012 was 49% (model range, 39%-58%) relative to the estimated baseline rate in 2012 of 63 deaths (model range, 54-73) per 100 000 women (Table 3 , column 3; eTable 2 in the Supplement). Hence, the estimated difference in the overall breast cancer mortality reduction in 2012 vs 2000 was 12% (model range, 10%-16%) ( Table 3 , column 4; eTable 5 in the Supplement). The estimated relative contribution associated with screening advances to this difference was 17% (model range, 2%-31%) ( Table 3 , column 5); treatment advances were 83% (model range, 69%-98%) ( Table 3 , sum of columns 6-8, with rounding; eTable 5intheSupplement). Of the 83% (model range, 69%-98%) treatment-related advances, 38% (model range, 21%-54%) was associated with advances in chemotherapy (largely taxanes); 29% (model range, 9%-44%) was associated with advances in 
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A, Based on data from multiple rounds of the National Health Interview Survey over time and Breast Cancer Surveillance Consortium (BCSC) data from 1994 to 2012. B, Based on Mammography Quality Standards Act of 1992 data on digital mammography facilities from the US Food and Drug Administration and the BCSC. C, An exemplar stage and set of molecular markers (node-positive AJCC 6 stage 2b, ER+/ERBB2−) at diagnosis based on data from Surveillance, Epidemiology, and End Results (SEER) special patterns of care studies and the National Comprehensive Cancer Network. These data were used for all other combinations of ages, stages, and molecular subtypes. In general, starting in the mid-1990s anthracycline-based, multiagent chemotherapy regimens were in use, and, in 1997, taxanes could be added to those regimens. Hormonal therapy began with tamoxifen in the 1980s and, starting in 1997, also included aromatase inhibitors. For women diagnosed with ERBB2+ tumors (not shown in this example), trastuzumab was disseminated independently of other treatments and, based on its immediate rapid uptake, all ERBB2+ patients were modeled as receiving trastuzumab beginning in year 2006. Models used 2010 treatment dissemination data for subsequent years (indicated by the dashed lines).
Breast Cancer Mortality by Molecular Subtype, 2000 Original Investigation Research jama.com (Reprinted) JAMA January 9, 2018 Volume 319, Number 2hormone therapy (largely the addition of aromatase inhibitors), and 15% (model range, 4%-25%) with the introduction of trastuzumab (Table 3, columns 6-8) .
Within each molecular subtype, the estimated difference in the breast cancer mortality reductions from 2000 to 2012 was largest for the ER+/ERBB2+ subtype at 19% (model range, 17%-25%) and the smallest for ER−/ERBB2− at 8% (model range, 5%-11%) ( Table 3 , column 4). The estimated relative contribution associated with screening and treatment to these differences also varied by subtype: the relative contribution associated with trastuzumab was 41% (model range, 27%-58%) in the ER+/ERBB2+ subtype and 57% (model range, 35%-78%) in ER−/ERBB2+ (Table 3 , column 8).
To complement the above analysis, we decomposed the overall mortality reduction in 2012 in terms of the contributions associated with advances before 2000 and after 2000 (eTable 6 in the Supplement). Of the 37% mortality reduction (model range, 27%-42%) associated with screening in 2012, 33% (model range, 29%-48%) was associated with screening advances before 2000 and 4% (model range, 1%-8%) after 2000 (largely digital mammography). The introduction of trastuzumab was associated with 15% of overall mortality reduction between 2000 and 2012. Of the 31% mortality reduction (model range, 23%-37%) associated with chemotherapy, 22% (model range, 15%-30%) was associated with chemotherapy advances before 2000 and 9% (model range, 7%-14%) after 2000 (largely taxanes). Of the 27% mortality reduction (model range, 18%-36%) associated with hormone therapy, 20% (model range, 15%-27%) was associated with advances in hormone therapy before 2000 and 7% (model range, 2%-12%) after 2000 (largely from aromatase inhibitors). eTable 6 in the Supplement provides subtype-specific results.
Discussion
This model-based analysis provides clinically relevant insights about the separate and combined population contributions associated with screening and treatment advances on reducing breast cancer mortality by molecular subtype. Six independent models found that both screening and treatment were associated with overall and subtype-specific breast cancer mortality decreases over time. Between 2000 and 2012, advances in treatment were associated with a larger contribution 
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Breast Cancer Mortality by Molecular Subtype, 2000 than screening to overall US breast cancer mortality decreases and for all molecular subtypes except ER−/ERBB2−, the subtype that also had the lowest modeled mortality reduction.
These results build upon past CISNET analyses and other studies that have examined the period before 2000 2, [30] [31] [32] or considered the role of ER− status. 15, 33 The current analysis Abbreviations: ER, estrogen-receptor; ERBB2; human epidermal growth factor receptor 2.
a The column labels are defined as follows:
b Relative to the estimated baseline mortality in 2012.
c These columns sum to 100%.
d Combined mortality reduction.
e Column 2 divided by column 4.
f Column 3 divided by column 4.
g Column 2 divided by the sum of columns 2 and 3. considered the study period from 2000 to 2012. In this period, digital mammography increased screening sensitivity compared with plain-film mammography, especially for women younger than 50 years and women with dense breasts, 34 and has increased somewhat the number of breast cancer deaths averted with screening. 35 The current results support findings that advances in mammography continue to contribute to reducing breast cancer mortality. It will be important to update the analysis when there is sufficient evidence about the benefits of tomosynthesis or other emerging screening approaches. 36, 37 Even with the recent screening advances, findings from this model-based analysis demonstrate a shift in the relative contributions associated with screening and treatment to breast cancer mortality, with greater contributions associated with treatment in 2012. Recent observational analyses have also Abbreviations: ER, estrogen-receptor; ERBB2; human epidermal growth factor receptor 2.
a Details on the computations are included in eMethods and eTable 5 in the Supplement. Briefly, in terms of means only, the overall mortality reduction between 2000 and 2012 associated with combined screening and treatment advances is estimated to be 12% (column 4). In 2012, the estimated relative contribution of screening to the mortality reduction associated with combined screening and treatment is 37% ( found stage-specific survival improvements related to current treatment. 33 The results from this model analysis confirm the benefits at the population level from the discovery and rapid dissemination over this past decade of several new classes of molecularly targeted therapies, improvements in delivery of standard regimens, and refinements in therapy based on molecular subtype according to ER and ERBB2 status. A unique contribution of this population-level analysis is how the relative contributions associated with screening and treatment varied by molecular subtype. In 2012, when gains from treatment alone were estimated, treatment alone could have been associated with roughly 70% of the predicted mortality reduction achieved with both screening and treatment for the all the subtypes expressing the ER, ERBB2 receptors, or both. However, screening is likely to remain important even if future treatments could cure all breast cancers because screening can detect disease at earlier stages, which has less surgical and treatment-related morbidity compared with more advanced stages.
Among the advances in recent adjuvant therapies, advances in chemotherapy with the addition of taxanes were associated with roughly 37% of the difference in overall breast cancer mortality reduction from 2000 to 2012. Advances in hormone therapy with the addition of aromatase inhibitors had comparable contribution associated with mortality reduction. The contribution associated with trastuzumab was smaller on overall mortality reduction (15%), because ERBB2+ cases account for approximately 20% of all newly diagnosed breast cancer cases, with variations based on age and race.
38 However, trastuzumab was associated with more than 40% of the difference in mortality reduction from 2000 to 2012 among the ERBB2+ subtypes.
All of the models concluded that the ER−/ERBB2− subtype had the lowest overall modeled mortality reduction over time, although the relative contributions associated with screening and treatment varied somewhat by model, with 3 of the 6 models estimating a modestly higher contribution associated with treatment compared with screening in 2012. Prior analysis of SEER data have similar results, with greater mortality declines for those with ER+ vs ER− tumors. 15, 39 Given that treatment advancements are lagging for ER−/ERBB2− cancers, more intensive screening approaches, or screening with different modalities, might be considered for groups at highest risk for this subtype, including African American women. Continued investments to discover molecularly targeted treatments for the ER−/ERBB2− subgroup remain important to continue to lower breast cancer death rates. Overall, the models projected that screening and treatment each were associated with continued reductions in breast cancer mortality, but, in 2012, treatment was associated with a larger relative proportion than screening of the mortality reductions overall and for all subtypes, except the ER−/ERBB2−. Because ER+ cancers are the most prevalent and this group is expected to increase with time, 40 additional advances for this subtype could have the largest effect on reducing the overall population burden of breast cancer. Looking ahead, modelbased approaches may continue to be important to evaluate continued population-level progress in reducing the burden of breast cancer through a combination of continued discovery and dissemination of effective molecularly targeted therapies, invention of novel screening technologies to optimize early detection of aggressive cancer subtypes, and greater ability to identify risk of developing specific molecular subtypes to permit tailored prevention and early detection. This study has several strengths. First, by synthesizing national and clinical trial data, the results fill an important knowledge gap, especially because current surveillance data systems do not contain information on both screening and treatment. Second, the main findings were robust across 6 independent models, despite differences in model structures and assumptions. Third, the validity of this comparative modeling approach is supported by the consistency of conclusions across models, and the ability of each model to closely replicate the patterns of observed trends in incidence and mortality.
Limitations
This research has several limitations. First, the accuracy of model results depends on the availability of good-quality data for input parameters and reasonable assumptions about unobservable events. For instance, because there are limited longterm clinical trial or registry data on survival by ERBB2 status, the models extrapolated long-term survival. Second, modeled treatment effects were based on efficacy in trials included in the Oxford Overview, 16 so there could be a slight overestimation of actual population treatment effects and the relative contribution of treatment to mortality reductions. Third, each model also made different assumptions about the baseline incidence and natural history of breast cancer, leading to variability in the magnitude of results. Fourth, the models considered only 5 years of hormonal therapy since recommendations to consider 10 years among women at high-risk of late recurrence were just recently introduced and have not yet been uniformly applied. Future modeling could incorporate the population-level dissemination and effectiveness of longerterm hormonal therapy. Fifth, progesterone-receptor status was not explicitly modeled because it is missing from many data sources. Sixth, subtype results for various racial/ethnic subgroups were not modeled. Understanding interactions between race, ethnicity, and subtype-specific outcomes represents an important future direction. 41 Seventh, the effect of screening and subtype-specific treatment on morbidity and allcause mortality was not evaluated. Eighth, modeling was based on estimates until 2012, and it is uncertain whether or how well these estimates reflect current breast cancer screening, treatment, or outcomes after 2012.
Conclusions
In this simulation modeling study that projected trends in breast cancer mortality rates among US women, decreases in overall breast cancer mortality from 2000 to 2012 were associated with advances in screening and in adjuvant therapy, although the associations varied by breast cancer molecular subtype. This supplementary material has been provided by the authors to give readers additional information about their work.
eMethods Computing the Relative Contributions Associated with Screening and Treatment
In the main text, the relative contribution associated with screening versus treatment to the combination was computed as the ratio of the screening alone mortality reduction divided by the sum of the screening alone mortality reduction and treatment alone mortality reduction; similarly for the relative contribution associated with treatment.
Herein, we refer to this approach as "Method A." Two alternative approaches for computing the relative contributions associated with screening and treatment were also considered. In "Method B," we evaluated the relative contributions associated with screening and treatment by first quantifying the contributions associated with screening alone and assigning the remainder of the combined effect to treatment. In "Method C", we evaluated the relative contributions associated with screening and treatment by first quantifying the contributions associated with treatment alone and assigning the remainder of the combined effect to screening. A comparison of all three approaches to compute the relative contributions associated with screening and treatment on overall breast cancer mortality is provided in Supplemental eTable 3. All three approaches provide the same ranking of relative contributions, but results differ because the combination associated with screening and treatment is less than the sum of the contributions associated with screening alone and treatment alone. If the combination was equal to the sum of screening alone and treatment alone, all three methods would give the same result.
Because Method A provided a result that was "in-between" Methods B and C, we choose it for the primary analysis.
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Computing the Relative Contributions Associated with Screening and Treatment to the Difference in the Reduction Between 2000 and 2012
In Table 3 of the main text, the relative contribution associated with screening and treatment advances to the different in the mortality reduction between 2000 and 2012 are
provided. The results in Table 3 To understand how the relative contributions associated with screening and treatment to the difference in the mortality reduction between 2000 and 2012 is computed, we describe the calculations based on overall mortality using the mean results in Table 3 . The overall mortality reduction associated with combined screening and 
Mammography dissemination
Screening dissemination is based on the age at first screening and frequency by birth cohort derived from BCSC and NHIS data through 2012
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